Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
Active, not recruiting · NCT02641093 · Registry updated 2026-05-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma | Head and Neck Neoplasms, Neoplasms by Site, head and neck cancer, neoplasm | Active, not recruiting | Phase 2 | 2026-05-04 | NCT02641093 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| Trisha Wise-Draper | 3 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| MD Anderson Cancer Center | Houston | United States | 589 |
| Medical University of South Carolina | Charleston | United States | 628 |
| Ohio State University | Columbus | United States | 169 |
| University of Cincinnati Medical Center | Cincinnati | United States | 83 |
| University of Louisville - James Graham Brown Cancer Center | Louisville | United States | 2 |
| University of Michigan | Ann Arbor | United States | 538 |